Avalo Therapeutics’ AVTX-009 is advancing in hidradenitis suppurativa, with Phase 2 data expected in 2026. Stifel initiates coverage with a $36 price target.
Latest Ratings for AVTX
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 2022 | Jefferies | Downgrades | Buy | Hold |
| Mar 2022 | RBC Capital | Maintains | Outperform | |
| Sep 2021 | RBC Capital | Initiates Coverage On | Outperform |
